ドキソルビシン

ドキソルビシン 化学構造式
23214-92-8
CAS番号.
23214-92-8
化学名:
ドキソルビシン
别名:
ヒドロキシダウノマイシン;ドキシル;アドリブラスチン;ルベックス;エバセト;ビオトランスドックス;ドキソルビシン;ケリックス;14-ヒドロキシダウノマイシン;アドリアマイシン;(8S)-10α-[(3-アミノ-2,3,6-トリデオキシ-α-L-lyxo-ヘキソピラノシル)オキシ]-7,8,9,10-テトラヒドロ-6,8α,11-トリヒドロキシ-8-(ヒドロキシアセチル)-1-メトキシ-5,12-ナフタセンジオン;(8S)-1-メトキシ-6,8α,11-トリヒドロキシ-8-(ヒドロキシアセチル)-10α-[(3-アミノ-2,3,6-トリデオキシ-α-L-lyxo-ヘキソピラノシル)オキシ]-7,8,9,10-テトラヒドロ-5,12-ナフタセンジオン;(8S,10S)-10-[(3-アミノ-2,3,6-トリデオキシ-α-L-lyxo-ヘキソピラノシル)オキシ]-8-グリコロイル-7,8,9,10-テトラヒドロ-6,8,11-トリヒドロキシ-1-メトキシ-5,12-ナフタセンジオン;(7S)-7,8,9,10-テトラヒドロ-6,9β,11-トリヒドロキシ-4-メトキシ-7β-[[(4S)-4α-アミノ-5α-ヒドロキシ-3,4,5,6-テトラヒドロ-6α-メチル-2H-ピラン]-2β-イルオキシ]-9α-ヒドロキシアセチルナフタセン-5,12-ジオン;(8S,10S)-10-{[(2R,4S,5S,6S)-4-アミノ-5-ヒドロキシ-6-メチルオキサン-2-イル]オキシ}-6,8,11-トリヒドロキシ-8-(2-ヒドロキシアセチル)-1-メトキシ-5,7,8,9,10,12-ヘキサヒドロテトラセン-5,12-ジオン;4-メトキシ-6,9β,11-トリヒドロキシ-7β-(4α-アミノ-5α-ヒドロキシ-6α-メチルテトラヒドロ-2H-ピラン-2β-イルオキシ)-9-(ヒドロキシアセチル)-7,8,9,10-テトラヒドロナフタセン-5,12-ジオン
英語名:
Adriamycin
英語别名:
DOXORUBICIN;Doxil;Rubex;Adriamycin PFS;HydroxydaunoMycin;Doxorubicin hydrohloride;10-((3-amino-2,3,6-trideoxy-alpha-l-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;(1s,3s)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside;(8S-cis)-10-(3-Amino-2,3,6-Trideoxy-alpha-L-Lyxo-Hexopyranosyl)Oxy-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-5,12-Naphthacenedione;(8S)-10-((4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
CBNumber:
CB1170865
化学式:
C27H29NO11
分子量:
543.53
MOL File:
23214-92-8.mol

ドキソルビシン 物理性質

融点 :
205°C
沸点 :
617.77°C (rough estimate)
比重(密度) :
1.3783 (rough estimate)
屈折率 :
1.6400 (estimate)
貯蔵温度 :
Keep in dark place,Sealed in dry,2-8°C
溶解性:
≥27.2 mg/mL in DMSO; insoluble in EtOH; ≥24.8 mg/mL in H2O with ultrasonic
外見 :
solid
酸解離定数(Pka):
pKa 8.2 (Uncertain)
水溶解度 :
溶ける
CAS データベース:
23214-92-8
IARC:
2A (Vol. 10, Sup 7) 1987
EPAの化学物質情報:
Doxorubicin (23214-92-8)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
HSコード  2941900000
有毒物質データの 23214-92-8(Hazardous Substances Data)
毒性 An anthracycline cytotoxic antineoplastic that is produced by Streptomyces peucetius. The LD50 in mice is 9.4 mg/kg, i.v. It is a carcinogen that inhibits DNA and RNA synthesis by intercalating in double-stranded DNA with the amino sugar in the minor groove and the 90-OH group of the anthracycline ring hydrogen-bonded to the adjacent guanine. It also alters membrane fluidity and ion transport, and generates free radicals through a cytochrome P450-mediated reductive process. In humans, it causes alopecia, stomatitis, nausea, vomiting, diarrhea, cardiotoxicity (manifested by tachycardia), and potentially fatal congestive heart failure.
絵表示(GHS) GHS hazard pictogramsGHS hazard pictograms
注意喚起語
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 皮膚刺激 皮膚腐食性/刺激性 2 警告 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 強い眼刺激 眼に対する重篤な損傷性/眼刺激 性 2A 警告 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 呼吸器への刺激のおそれ 特定標的臓器毒性、単回暴露; 気道刺激性 3 警告 GHS hazard pictograms
H350 発がんのおそれ 発がん性 1A, 1B 危険 GHS hazard pictograms
H362 授乳中の子に害を及ぼすおそれ 生殖毒性、授乳に対するまたは 授乳を介したの影響 追加区分 P201, P260, P263, P264, P270,P308+P313
注意書き
P260 粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。
P263 妊娠中/授乳期中は接触を避けること。
P280 保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

ドキソルビシン 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

ドキソルビシン 化学特性,用途語,生産方法

解説

塩ドキソルビシン,赤橙色の針状晶.分解点204~205 ℃.[α]20D+248°(メタノール).UV(メタノール)λmax 233,252,288,479,496,529 nm.DNAに層間挿入して核酸合成を阻害する.トポイソメラーゼⅡを阻害してDNA鎖切断をする.急性リンパ性白血病,リンパ腫,乳がん,小細胞肺がん,卵巣がんなどの治療に広く使われる.

森北出版「化学辞典(第2版)

用途

ドキソルビシン(doxorubicin)は、抗悪性腫瘍剤(抗がん剤)の一種。

製造

ドキソルビシン,アドリアマイシンともいう.Streptomyces peucetius var caesiusが産生するアンスラサイクリン系抗生物質.

効能

抗悪性腫瘍薬, トポイソメラーゼII阻害薬

毒性

LD50 698 mg/kg(マウス,経口).

化学的特性

Adriamycin is an orange to red cake-like or needle-like crystalline solid.

使用

Doxorubicin (adriamycin) is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumour agent for the treatment of a wide range of cancers. Doxorubicin also exhibits anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.

適応症

Doxorubicin binds tightly to DNA by its ability to intercalate between base pairs and therefore is preferentially concentrated in nuclear structures. Intercalation results in steric hindrance, hence production of single-strand breaks in DNA and inhibition of DNA synthesis and DNA-dependent RNA synthesis. The enzyme topoisomerase II is thought to be involved in the generation of DNA strand breaks by the anthracyclines. Cells in S-phase are most sensitive to doxorubicin, although cytotoxicity also occurs in other phases of the cell cycle.

作用機序

Doxorubicin is not absorbed orally, and because of its ability to cause tissue necrosis must not be injected intramuscularly or subcutaneously. Distribution studies indicate rapid uptake in all tissues except the CNS. Extensive tissue binding, primarily intranuclear, accounts for the prolonged elimination half-life.The drug is extensively metabolized in the liver to hydroxylated and conjugated metabolites and to aglycones that are primarily excreted in the bile.

臨床応用

Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin’s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing’s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non–oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis.

副作用

The most important toxicities caused by doxorubicin involve the heart and bone marrow.Acutely, doxorubicin may cause transient cardiac arrhythmias and depression of myocardial function. Doxorubicin may cause radiation recall reactions, with flare-ups of dermatitis, stomatitis, or esophagitis that had been produced previously by radiation therapy. Less severe toxicities include phlebitis and sclerosis of veins used for injection, hyperpigmentation of nail beds and skin creases, and conjunctivitis. Because of its intense red color, doxorubicin will impart a reddish color to the urine for 1 or 2 days after administration.

安全性プロファイル

Confirmed carcinogen with experimental carcinogenic, neoplastigenic, and tumorigenic data. Poison by intraperitoneal, subcutaneous, parenteral, and intravenous routes. Human systemic effects by intravenous route: cardiac myopathy including infarction, nausea or vomiting, and effects on the hair. An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NO, and HCl

職業ばく露

An antibiotic product from streptomyces, used as anticancer drug

発がん性

Adriamycin is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

輸送方法

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

不和合性

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides

廃棄物の処理

It is inappropriate and possibly dangerous to the environment to dispose of expired or waste pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

ドキソルビシン 上流と下流の製品情報

原材料

準備製品


ドキソルビシン 生産企業

Global( 256)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12456 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618740459177
sarah@tnjone.com China 874 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21691 55
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Shenzhen Nexconn Pharmatechs Ltd
+86-755-89396905 +86-15013857715
admin@nexconn.com China 10248 58
Hebei Guanlang Biotechnology Co., Ltd.
+86-19930503282
alice@crovellbio.com China 8823 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873
sales@chemdad.com China 39916 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 47465 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569266 15319487004
1015@dideu.com China 2263 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58

ドキソルビシン  スペクトルデータ(1HNMR)


23214-92-8(ドキソルビシン)キーワード:


  • 23214-92-8
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • ADRIAMYCIN
  • 14-Hydroxydaunomycin
  • adiblastine (hydrochloride salt)
  • adriablastine (hydrochloride salt)
  • adriablatina (hydrochloride salt)
  • Adriacin (hydrochloride salt)
  • Adriamycin PFS (hydrochloride salt)
  • Adriamycin RDF
  • Adriamycin RDF (hydrochloride salt)
  • Adriblastin
  • Adriblastina (hydrochloride salt)
  • adriblatina (hydrochloride salt)
  • Doxorubicin hydrochloride (hydrochloride salt)
  • Farmablastina (hydrochloride salt)
  • Hydroxydaunomycin hydrochloride (hydrochloride salt)
  • Hydroxydaunorubicin hydrochloride (hydrochloride salt)
  • Rubex (hydrochloride salt)
  • 5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • NSC 123127
  • ADRIAMYCINSEMIQUINONE
  • (85-cis)-10-[(3-amino-2,3,6-trideoxy-alpha-l-lyxohexapyranosyl)oxy]-7,8,9,10- t
  • adriamycine
  • etrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • DOXOPINHYDROCHLORIDE
  • (85-Cis)-10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-methoxy-5,12-Naphthacenedione
  • (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
  • ヒドロキシダウノマイシン
  • ドキシル
  • アドリブラスチン
  • ルベックス
  • エバセト
  • ビオトランスドックス
  • ドキソルビシン
  • ケリックス
  • 14-ヒドロキシダウノマイシン
  • アドリアマイシン
  • (8S)-10α-[(3-アミノ-2,3,6-トリデオキシ-α-L-lyxo-ヘキソピラノシル)オキシ]-7,8,9,10-テトラヒドロ-6,8α,11-トリヒドロキシ-8-(ヒドロキシアセチル)-1-メトキシ-5,12-ナフタセンジオン
  • (8S)-1-メトキシ-6,8α,11-トリヒドロキシ-8-(ヒドロキシアセチル)-10α-[(3-アミノ-2,3,6-トリデオキシ-α-L-lyxo-ヘキソピラノシル)オキシ]-7,8,9,10-テトラヒドロ-5,12-ナフタセンジオン
  • (8S,10S)-10-[(3-アミノ-2,3,6-トリデオキシ-α-L-lyxo-ヘキソピラノシル)オキシ]-8-グリコロイル-7,8,9,10-テトラヒドロ-6,8,11-トリヒドロキシ-1-メトキシ-5,12-ナフタセンジオン
  • (7S)-7,8,9,10-テトラヒドロ-6,9β,11-トリヒドロキシ-4-メトキシ-7β-[[(4S)-4α-アミノ-5α-ヒドロキシ-3,4,5,6-テトラヒドロ-6α-メチル-2H-ピラン]-2β-イルオキシ]-9α-ヒドロキシアセチルナフタセン-5,12-ジオン
  • (8S,10S)-10-{[(2R,4S,5S,6S)-4-アミノ-5-ヒドロキシ-6-メチルオキサン-2-イル]オキシ}-6,8,11-トリヒドロキシ-8-(2-ヒドロキシアセチル)-1-メトキシ-5,7,8,9,10,12-ヘキサヒドロテトラセン-5,12-ジオン
  • 4-メトキシ-6,9β,11-トリヒドロキシ-7β-(4α-アミノ-5α-ヒドロキシ-6α-メチルテトラヒドロ-2H-ピラン-2β-イルオキシ)-9-(ヒドロキシアセチル)-7,8,9,10-テトラヒドロナフタセン-5,12-ジオン
  • アントラサイクリン系抗生物質
  • テトラサイクリン類
Copyright 2017 © ChemicalBook. All rights reserved